NCT05741437已完成1 期
A Randomized, Open-label, Single-dose, Two-way Crossover Clinical Trial to Investigate the Pharmacokinetics and Safety After Oral Administration of CKD-378 and Co-administration of D745, D150 in Healthy Adults
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 24
- 试验地点
- 2
- 主要终点
- 1. AUCt of CKD-378: Area under the concentration-time curve time zero to time
研究概览
简要总结
A clinical trial to compare and evaluate the safety and pharmacokinetics of CKD-378
详细描述
A Randomized, Open-label, Single-dose, Two-way Crossover Clinical Trial to Investigate the Pharmacokinetics and Safety after Oral Administration of CKD-378 and Co-administration of D745, D150 in Healthy Adults
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 19 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy adult aged between 19 to 55 at screening
- •Weight ≥ 50kg(man) or 50kg(woman)
- •Body mass index (BMI) of 18.5 to 27.0kg/m2
- •If female, one of following conditions. Menopause (no menstruation more than 2 years) or surgically sterilized.
- •Those who agree to contraception from the first IP dosing day till 28 days after the last dosing day and decide not to provide sperm during the participation of clinical trial
- •Those who voluntarily decide to participate in paper and agree to comply with the cautions after fully understand the detailed description of this clinical trial
排除标准
- •Those who have clinically significant disease or medical history of Hepatopathy, Renal dysfunction, Neurological disorder, Immunity disorder, Respiratory disorder, Genitourinary system disorder, Haemato-oncology disorder, Cardiovascular disorder or Psychical disorder.
- •Those who are vulnerable to dehydration due to lack of ability in oral intake or have dehydration.
- •Those who had medical examination requiring radioactive iodine contrast material injected through IV 48 hours prior to first IP administration.
- •Those who have significant disease or medical history of urinary infection.
- •Those who have genetic problems such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption
- •Those who have a history of gastrointestinal surgery except simple appendectomy and hernia surgery which can interfere with drug absorption.
- •Those who have hypersensitivity to the main constituents or components of the investigational drug such as empagliflozin, metformin.
- •Those who have tested inappropriate in screening test 28 days prior to IP administration.
- •AST, ALT > 1.5 times higher than upper normal level
- •eGFR (estimated Glomerular Filtration Rate, which is calculated by MDRD) < 60 mL/min/1.73m2
- •"Positive" or "Reactive" test result of Hepatitis B & C, HIV, RPR
- •Under 5 min resting condition, systolic blood pressure >150 mmHg or or <90 mmHg, diastolic blood pressure >100 mmHg or <50 mmHg.
- •Those who has a drug abuse history within one year or positive reaction on urine drug screening test.
- •Woman who are pregnant or breastfeeding
- •Those who exceed an alcohol, caffeine and cigarette consumption (caffeine> 5 cups/day, alcohol> 210g/week, smoking> 10 cigarettes/day) and not able to stop on smoking, caffeine and alcohol
- •Those who have used following drugs that can interfere with the study or have impact on safety of the subject.
- •ETC, herbal medicinal preparations within 14 days before the first dosing date
- •OTC, vitamins, health supplement within 7 days before the first dosing date
- •Depot injection or implantation within 30 days before the first dosing date
- •Those who received investigational products or participated in bioequivalence test within 180 days before the first administration of clinical trial drugs
- •Those who donated whole blood within 60 days before the first date of administration and donated ingredients within 30 days
- •Those who have received blood transfusion in 30 days
- •Those who are deemed insufficient to participate in clinical study by investigators
研究组 & 干预措施
Sequence 1
Experimental
- Period 1: D745, D150 - A single oral dose of 2 tablets under food intake condition
- Period 2: CKD-378 - A single oral dose of 1 tablet under food intake condition
干预措施: CKD-378, QD, PO Drug: D745, D150, QD, PO (Drug)
Sequence 2
Experimental
- Period 1: CKD-378 - A single oral dose of 1 tablet under food intake condition
- Period 2: D745, D150 - A single oral dose of 2 tablets under food intake condition
干预措施: CKD-378, QD, PO Drug: D745, D150, QD, PO (Drug)
结局指标
主要结局
1. AUCt of CKD-378: Area under the concentration-time curve time zero to time
时间窗: Pre-dose(0 hour) to 48 hours
2. Cmax of CKD-378: Maximum plasma concentration of the drug
时间窗: Pre-dose(0 hour) to 48 hours
次要结局
未报告次要终点
研究者
研究点 (2)
Loading locations...
相似试验
已完成
1 期
Clinical Trial to Investigate the Pharmacokinetics and Safety After Oral Administration of CKD-378 and Co-administration of D745, D150, D029 in Healthy AdultsType II DiabetesNCT05881213Chong Kun Dang Pharmaceutical23
已完成
1 期
A Clinical Trial to Evaluate the Pharmacokinetic Profiles and Safety of CKD-383.Type2 Diabetes MellitusNCT04810676Chong Kun Dang Pharmaceutical27
已完成
1 期
A Study to Investigate the PK and Safety of CKD-393Type II DiabetesNCT04768673Chong Kun Dang Pharmaceutical26
已完成
1 期
A Clinical Trial to Evaluate the Pharmacokinetics and Tolerability of CKD-348Hypertension and DyslipidemiaNCT04587206Chong Kun Dang Pharmaceutical62
已完成
1 期
A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-348Hypertension and DyslipidemiaNCT04660370Chong Kun Dang Pharmaceutical70